MedTrace Logo

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

NCT00758784 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-09-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.

Conditions

Interventions

DRUG

bromfenac ophthalmic solution 0.06%

bromfenac ophthalmic solution 0.06% bilaterally twice a day

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Tim McNamara, PharmD · ISTA Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-13
Primary Completion
2009-01-14
Completion
2009-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00758784 on ClinicalTrials.gov